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Aim: We investigated uptake of short-course chemo-radiotherapy and compared outcomes with other
treatment schedules in elderly patients with glioblastoma (GBM).Methods: Patients aged 65 or over with
a diagnosis of GBM were identified from an 18-month period from three centers in the UK. The primary
end point of this study was overall survival from the date of diagnosis. Results: The analysis included 210
patients. Overall median survival was 5.0 months. Approximately 31.9% of patients received combined
chemoradiation; multivariate analysis showed that patients who received standard chemoradiation were
at a reduced risk of death than those receiving hypofractionated chemoradiation.Discussion: In this retro-
spective study, patients treated with standard chemoradiation experienced better outcomes than patients
receiving hypofractionated chemoradiation. Patient selection likely contributed to these findings.
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Glioblastoma (GBM) is a primary brain tumor that confers a very poor prognosis [1]. Elderly patients (generally
defined as age ≥65 years) represent nearly half of the GBM population and have a median survival of 7.2 months
compared with 11.2 months in the nonelderly population [2–4].
Standard management of GBM comprises surgical resection followed by standard radiotherapy (60 Gy in 30
fractions) with concomitant and adjuvant temozolomide chemotherapy, as defined by Stupp et al. [5]. While this
treatment strategy has improved overall survival for younger patients with GBM, elderly patients were underrepre-
sented in the study and those over 70 were excluded. Subgroup analysis showed no survival benefit from adding
chemotherapy to radiotherapy in patients aged 66–70 [6].
Several randomized Phase III trials have addressed uncertainties surrounding the management of GBM in
elderly patients [7–9]. Roa et al. [8] compared standard radiotherapy to hypofractionated radiotherapy (40 Gy in 15
fractions) and Wick et al. [7] compared chemotherapy only (temozolomide) to standard radiotherapy, with neither
study finding a difference in survival. The most recent study, undertaken by Perry et al. [9], demonstrated that
adding concomitant and adjuvant temozolomide to hypofractionated radiotherapy significantly improved survival
in elderly patients compared with hypofractionated radiotherapy alone (9.3 vs 7.6 months; hazard ratio for death
0.67; p < 0.001) However, no direct comparisons have yet been made between standard and hypofractionated
chemo-radiotherapy, and many clinicians prefer to offer the standard regimen to patients aged 65 and over who
have good performance status. With this in mind, we undertook a retrospective study of the management of
elderly patients with GBM in three UK centers, to evaluate the use of hypofractionated chemo-radiotherapy and
to estimate overall survival in patients receiving different treatment regimens.
Patients & methods
This retrospective study was conducted in three UK centers: Beatson West of Scotland Cancer Centre (Glasgow),
Christie Hospital (Manchester) and Sussex Cancer Centre (Brighton). These were selected as tertiary cancer care
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centers with large catchment areas representing diverse UK regions. Patients were identified from neuro-oncology
multi-disciplinary team (MDT) meeting lists between 1 July 2016 and 31 December 2017. Inclusion criteria were
broad: aged 65 and over; diagnosis of GBM made either by pathology or radiology as confirmed by a consultant
neuro-radiologist in anMDTmeeting and no involvement in a therapeutic clinical trial. Clinical data were collected
retrospectively from electronic patient information databases using MDT notes, clinical letters, operation notes,
radiology and pathology reports as primary sources. Follow-up data was collected up to 18 March 2019. As this
was an audit, approval by an ethics review committee was not required.
Clinical characteristics
Baseline information comprised age, sex, Eastern Cooperative Oncology Group (ECOG) performance status (PS)
and date of diagnosis, defined either as date of surgery or date of diagnostic radiological imaging if no histological
diagnosis was available.
Management
Chemotherapy and radiotherapy treatment details were recorded, including radiotherapy dose, number of fractions
and whether treatment was completed. Standard radiotherapy was defined as 60 Gy in 30 fractions and hypofrac-
tionated radiotherapy as 40 Gy in 15 fractions. Surgery was classified into gross total resection (>90% tumor
resection), subtotal resection (<90% tumor resection) and biopsy.
Pathology
Pathological diagnosis and tumor grade were based on the WHO classification of 2007. Information on IDH-1
and MGMT promoter methylation status were recorded where available.
Statistical analyses
Chi-square and Mann–Whitney tests were used to investigate differences in distributions of patient characteristics
by treatment group. To visualize overall mortality, Kaplan Meier survival curves were plotted, and log-rank tests
were used to evaluate differences between treatment groups. Median survival times were estimated and presented
with 95% CIs. For patients who had received combined chemotherapy and radiotherapy, Cox’s proportional
hazards regression was used to produce univariate, traditional multivariable adjusted and propensity score adjusted
hazard ratios for hypofractionated radiotherapy versus standard radiotherapy. Treatment regimen, sex, age and PS
were included as factors which may have had a bearing on patient outcome. To account for imbalances in the
distribution of these covariates, propensity scores were calculated using logistic regression, with treatment group
(hypofractionated radiotherapy) as the outcome and age, sex, PS and treatment center as predictors of treatment
received; adjustments were made by including the resulting propensities when modeling hazard ratios. Median
follow-up time was estimated using the reverse Kaplan Meier method. All tests were two-sided, p-values less than
0.05 were considered statistically significant. All analyses were performed using STATA v14.2 (StataCorp, TX,
USA).
Results
Demographics
A total of 217 patients with a diagnosis of GBM and aged over 65 years were identified. Four patients were excluded
because of participation in a clinical trial and three were excluded due to insufficient information, leaving 210
patients included in the final analysis. Table 1 shows the patient characteristics. Mean age was 74.2 years (standard
deviation 6.29) and 56.2% of patients were males. The most commonly reported PS score was 1 (35% of patients)
and ranged from 0 (11%) to 3+ (30%).
Diagnosis & genetic testing
A diagnosis of GBM was made via histopathological examination in 122 patients, and by radiological confirmation
by a consultant neuro-radiologist in 88 patients. Tumor specimens from 80 patients (38%) underwent testing
for MGMT promoter methylation status, of which 25 were methylated, 50 were unmethylated and five did not
yield a result. Immunohistochemical IDH-1 data were available for 108 patients, of whom only one exhibited
IDH-1mutation. Neurosurgery was performed on 126 patients as detailed in Table 1. In total, 30 patients (23.8%)
underwent stereotactic biopsy, 58 (46.0%) subtotal resection and 37 (29.4%) gross total resection.
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Table 1. Patient characteristics by treatment regimen.
Patient characteristics All patients Chemotherapy and
radiotherapy
Chemotherapy only Radiotherapy only Supportive treatment
Number 210 67 (31.9) 16 (7.6) 23 (11.0) 104 (49.5)
Mean age (SD) 74.2 (6.29) 69.8 (4.0) 72.5 (6.1) 72.5 (6.0) 76.8 (6.0)
Age group (years):
– 65–70
– 70–75
– 75+
71 (33.8)
50 (23.8)
89 (42.4)
40 (59.7)
18 (26.9)
9 (13.4)
7 (43.8)
2 (12.5)
7 (43.8)
10 (43.5)
6 (26.1)
7 (30.4)
14 (13.5)
24 (23.1)
66 (63.5)
Sex:
– Men
– Women
118 (56.2)
92 (43.8)
35 (52.2)
32 (47.8)
8 (50.0)
8 (50.0)
14 (60.9)
9 (39.1)
61 (58.7)
43 (41.3)
Performance status:
– 0
– 1
– 2
– 3+
– Unknown
23 (11.0)
73 (34.8)
41 (19.5)
61 (29.0)
12 (5.7)
17 (25.4)
31 (46.3)
9 (13.4)
5 (7.5)
5 (7.5)
1 (6.3)
12 (75.0)
2 (12.5)
1 (6.3)
0 (0.0)
2 (8.7)
9 (39.1)
7 (30.4)
3 (13.0)
2 (8.7)
3 (2.9)
21 (20.2)
23 (22.1)
52 (50.0)
5 (4.8)
Treatment center:
– Glasgow
– Brighton
– Manchester
100 (47.6)
37 (17.6)
73 (34.8)
16 (23.9)
9 (13.4)
42 (62.7)
16 (100.0)
0 (0.0)
0 (0.0)
3 (13.0)
6 (26.1)
14 (60.9)
65 (62.5)
22 (21.2)
17 (16.3)
MGMT promoter methylation:
– Tested
– Methylated
– Unmethylated
– Failed testing
80
25 (31.3)
50 (62.5)
5 (6.3)
32
9 (28.1)
23 (71.9)
2 (6.3)
16
10 (62.5)
6 (37.5)
0 (0.0)
9
2 (22.2)
6 (66.7)
1 (11.1)
21
4 (19.0)
15 (71.4)
2 (9.5)
Neurosurgery:
– Stereotactic biopsy
– Subtotal resection 90%
– Gross total resection 90%
– Unknown surgery
– No surgery
30 (14.3)
58 (27.6)
37 (17.6)
1 (4.8)
84 (40.0)
7 (10.4)
42 (62.7)
18 (26.9)
0 (0.0)
0 (0.0)
7 (43.8)
4 (25.0)
4 (25.0)
1 (6.3)
0 (0.0)
6 (26.1)
4 (17.4)
6 (26.1)
0 (0.0)
7 (30.4)
10 (9.6)
8 (7.7)
9 (8.7)
0 (0.0)
77 (74.0)
Diagnosis:
– Pathological diagnosis
– Radiological diagnosis
122 (58.1)
88 (41.9)
67 (100.0)
0 (0.0)
16 (100.0)
0 (0.0)
16 (69.6)
7 (30.4)
23 (22.1)
81 (77.9)
The numbers in brackets represent percentages unless indicated otherwise.
SD: Standard deviation.
Treatment
Just under half of patients (104, 49.5%) received supportive care and did not receive either chemotherapy or
radiotherapy. Out of the 106 patients who received active treatment, radiotherapy with concurrent and/or adjuvant
chemotherapy was prescribed for 63.2%, while smaller proportions received either radiotherapy or chemotherapy
alone (21.7 and 15.1% respectively). Patients who received supportive care were older (63.5 vs 21.7% aged 75
and over; p < 0.001) and had poorer PS (50.0 vs 8.5% with PS 3+; p < 0.001) compared with the patients who
received active treatment.
Patients treated with chemotherapy & radiotherapy
Of the 67 patients treated with chemo-radiotherapy, 59.7% received standard radiotherapy, 34.3% hypofraction-
ated radiotherapy and 6.0% other radiotherapy regimens (Table 2). In total, 63 patients received concomitant
chemotherapy (temozolomide) and four received adjuvant chemotherapy only. Compared with patients who re-
ceived standard chemoradiation, those who received hypofractionated chemoradiation were older (27.5 vs 56.5%
aged 70 and over; p = 0.022) and had poorer PS (13.0 vs 32.5% with PS 0; p = 0.05).
High rates of treatment compliance with radiotherapy were observed in both groups. All 23 patients receiving
hypofractionated radiotherapy and 37 of the 40 patients receiving standard radiotherapy completed treatment, and
the few patients receiving other schedules also completed treatment.
Chemotherapy data are summarized in Table 3. Temozolomide was the only chemotherapy agent received by
the study population. Out of the 23 patients receiving hypofractionated chemo-radiotherapy, 21 (91.3%) received
concomitant temozolomide and two received adjuvant chemotherapy only. Ten of the 21 patients who received
concomitant temozolomide went on to receive adjuvant chemotherapy. All 40 patients receiving standard chemo-
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Table 2. Patient characteristics for patients who received radiotherapy and chemotherapy.
Hypofractionated radiotherapy and
chemotherapy
Standard radiotherapy and
chemotherapy
Other radiotherapy regimen and
chemotherapy
Numbers 23 (34.3) 40 (59.7) 4 (6.0)
Mean age (SD) 71.0 (3.8) 68.8 (3.8) 72 (4.5)
Age group:
– 65–70
– 70–75
– 75+
10 (43.5)
8 (34.8)
5 (21.7)
29 (72.5)
8 (20.0)
3 (7.5)
1 (25.0)
2 (50.0)
1 (25.0)
Sex:
– Men
– Women
12 (52.2)
11 (47.8)
20 (50.0)
20 (50.0)
3 (75.0)
1 (25.0)
Performance status:
– 0
– 1
– 2
– 3+
– Unknown
3 (13.0)
14 (60.9)
3 (13.0)
2 (8.7)
1 (4.3)
13 (32.5)
16 (40.0)
5 (12.5)
2 (5.0)
4 (10.0)
1 (25.0)
1 (25.0)
1 (25.0)
0 (0)
0 (0.0)
Treatment center:
– Glasgow
– Brighton
– Manchester
9 (39.1)
2 (8.7)
12 (52.2)
7 (17.5)
7 (17.5)
26 (65.0)
0 (0.0)
0 (0.0)
4 (100.0)
The numbers in brackets represent percentages unless indicated otherwise.
SD: Standard deviation.
Table 3. Chemotherapy regimen prescribed and completion of chemotherapy based on radiotherapy regimen prescribed.
Radiotherapy dose Concomitant
chemotherapy (n)
Completed concomitant
(n)
Completion rates for
concomitant
chemotherapy
Adjuvant after
concomitant
chemotherapy (n)
Adjuvant only (n)
Hypofractionated
radiotherapy
21 19 90.5% 10 2
Standard radiotherapy 40 35 87.5% 33 0
Other radiotherapy 2 1 50% 2 2
Table 4. Patients who received radiotherapy only grouped by radiotherapy regimen and rate of completion of
radiotherapy.
Radiotherapy dose Frequency Patients who completed radiotherapy (%)
60 Gy in 30 fractions 1 0%
40 Gy in 15 fractions 10 80%
30 Gy in 6 fractions 11 90.9%
50 Gy in 25 fractions 1 100%
radiotherapy received concomitant chemotherapy. Completion rates for concomitant chemotherapy were similar:
90.5% in the hypofractionated group and 87.5% in the standard group (p = 0.7). Adjuvant therapy was offered to
33 patients after standard treatment. Information on completion of adjuvant chemotherapy was incomplete and
therefore not reported.
Patients in other treatment groups
Sixteen patients received chemotherapy only in the form of temozolomide. Information about dose and number
of cycles was incomplete and is therefore not reported.
As shown in Table 4, 23 patients received radiotherapy only. Of these, ten were prescribed 40 Gy in 15 fractions,
of whom 80% completed the course; 11 were prescribed 30 Gy in six fractions, of whom 91% completed. One
patient prescribed 50 Gy in 25 fractions completed the course while one patient prescribed 60 Gy in 30 fractions
did not.
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Figure 1. Kaplan-Meier survival curves based on treatment type received.
Survival outcomes
The median follow-up was 22.6 months, during which 188 patients (89.5%) died. Median overall survival for the
entire group was 5.0 months (95% CI: 3.8–6.2 months). Figure 1 shows the survival curves based on treatment
received. Patients who received active treatment had a median survival of 9.0 months (95% CI: 7.6–10.9), whereas
patients who received supportive care had a median survival of 2.5 months (95% CI: 2.1–3.2). Among actively
treated patients, those who received chemo-radiotherapy experienced higher overall survival (11.5 months) than
those who received either chemotherapy (5.4 months) or radiotherapy (6.0 months) alone (p = 0.0005).
There was no statistically significant difference in survival by treatment center (p = 0.75), PS (p = 0.81) or
MGMT promoter methylation status (p = 0.41) among actively treated patients (Table 5).
Median overall survival of patients who received standard chemo-radiotherapy was increased by just over
2 months compared with survival among those receiving hypofractionated chemo-radiotherapy (12.5 months
[95% CI: 10.3–14.1] vs 10.2 months [5.0–11.5], respectively, p = 0.026). The corresponding survival curves are
shown in Figure 2. Tables 6 & 7 show univariate and multivariate adjusted hazard ratios for overall survival, taking
account of clinical and treatment characteristics. Hazard of death was increased among patients who received
hypofractionated radiotherapy compared with patients who received standard radiotherapy. No other variables
showed a statistically significant association with survival in the univariate analysis, although women displayed
a reduced hazard compared with men and patients with a PS of 1 or more showed an increase in the hazard
of death. Patients receiving hypofractionated radiotherapy continued to show an increased hazard of death in
multivariable analyses adjusting for sex, age and PS. The increased hazard persisted when adjustment was made
for the propensity of patients to receive hypofractionated radiotherapy. The hazard ratio of death among patients
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Table 5. Median survival for patients who received active treatment.
Number Median survival (months) 95% CI Log rank test p-value
Actively treated 106 9.0 3.8–6.2
Combined chemotherapy and
radiotherapy:
67 11.5 9.2–12.7 0.0005
– Hypofractionated
radiotherapy
23 10.2 5.0–11.5
– Standard radiotherapy 40 12.5 10.3–14.1
– Other radiotherapy 4 5.5 5.5 to not reached
Chemotherapy only 16 5.4 3.1–7.6
Radiotherapy only 23 6.0 2.7–9.0
Glasgow 35 8.3 5.4–10.7 0.75
Brighton 15 10.3 6.6–11.1
Manchester 56 9.2 6.2–12.5
PS score (0–1) 72 8.3 6.2–10.7 0.82
PS score (2–4) 27 9.8 6.0–12.5
MethylatedMGMT promoter 21 8.6 4.1–18.1 0.41
UnmethylatedMGMT promoter 35 10.2 7.6–11.2
PS: Performance status.
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Figure 2. Kaplan-Meier survival curves comparing standard radiotherapy and chemotherapy versus
hypofractionated radiotherapy and chemotherapy.
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Table 6. Hazard ratios for death associated with patient and treatment characteristics for patients who
received combined chemotherapy and radiotherapy.
Characteristics Univariable Multivariable
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
Fractionation:
– Standard
– Hypofractionated
1
1.89 (1.07–3.34) 0.03
1
2.20 (1.15–4.21) 0.02
Sex:
– Men
– Women
1
0.69 (0.39–1.22) 0.21
1
0.59 (0.32–1.07) 0.08
Age group:
– 65-70
– 70+
1
1.01 (0.57–1.78) 0.99
1
0.79 (0.43–1.44) 0.44
Performance status:
– 0
– 1+
– Unknown
1
1.26
0.85
(0.65–2.45)
(0.27–2.66)
0.49
0.78
1
0.89
0.49
(0.43–1.84)
(0.14–1.68)
0.76
0.26
Table 7. Hazard ratios adjusting for propensity score.
Variables Multivariable adjusting for propensity
score (continuous)
Multivariable adjusting for propensity
score (categorical)
Multivariable stratified by propensity
score category
HR 95% CI p-value HR 95% CI p-value HR 95%CI p-value
Fraction:
– Standard
– Hypo 12.42 1.23–4.78 0.01
1
2.36 1.23–4.52 0.01
1
2.32 1.18–4.56 0.01
Propensity score 0.39 0.09–1.60 0.19
Propensity score:
– 0.25
– 0.25–0.5
– 0.5–0.75
– 0.75+
1
0.87
0.77
0.36
0.32–2.41
0.40–1.47
0.08–1.68
0.79
0.43
0.19
HR: Hazard ratio.
receiving hypofractionated radiotherapy compared with standard fractionation ranged from 2.2 to 2.4 depending
on the multivariable model employed.
Discussion
While an increasing body of evidence to guide the management of elderly patients with GBM has been published
in recent years, a number of uncertainties remain. Despite Perry et al.’s study [9] showing that addition of TMZ to
short course radiotherapy improved survival, no trials have directly compared short course with standard chemo-
radiotherapy. The main aim of our study was to evaluate the use of hypofractionated chemo-radiotherapy, and
to investigate any differences in outcome between elderly GBM patients receiving short course and standard
chemoradiation. While the observational and retrospective nature of this study render it susceptible to bias from
selection by indication, we reasoned that its findings would be important because a randomized study of standard
versus hypofractionated chemoradiation was unlikely to be conducted.
Our study showed that hypofractionated chemo-radiotherapywas delivered to 21.7%ofGBMpatients aged 65 or
above who received active treatment, and that this regimen yielded similar outcomes to those reported by Perry and
colleagues in the recent National Cancer Institute of Canada Clinical Trials Group (NCIC) Elderly Study (median
overall survival 10.2 months compared with 9.3 months, respectively) [9]. Despite the publicity surrounding these
data, 37.7% of the actively treated patients in this age group received standard chemo-radiotherapy (60 Gy in 30
fractions). Of note, these patients had a lower risk of death than those receiving hypofractionated chemoradiation.
The risk of death continued to be reduced after adjusting for age, sex, PS and the propensity of patients to receive
hypofractionated radiotherapy.
It might be reasonable to assume that patients with better prognostic and predictive characteristics would have
been offered standard radiotherapy and chemotherapy rather than hypofractionated radiotherapy and chemotherapy
by the treating oncologist. Therefore, we would have expected patients who received standard radiotherapy and
chemotherapy to have better survival. We tried to account for this by creating a propensity score and included
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this in the survival analysis. A limitation is that there may be unmeasured confounders that influence treatment
assignment such as patient preference and clinician decision. The completion rates for adjuvant chemotherapy in
patients who received hypofractionated chemo-radiotherapy were incomplete and not considered in the analysis.
This may have had a confounding influence on the results observed.
Given the limitations of this retrospective study, we do not claim that these findings advocate against the use of
hypofractionated chemo-radiotherapy. Rather they highlight the need for a personalized approach to therapy for
elderly GBM patients and, more specifically, the urgent need for validated assessment tools to improve patient and
treatment selection.
This study was limited by the relatively small sample size of 210 patients. In particular, subgroup analysis
of hypofractionated versus standard chemo-radiotherapy involved only 63 patients. Furthermore, patients were
not stratified according to neurosurgical intervention (biopsy, subtotal resection, gross-total resection) because of
the small sample size, which may have a confounding effect on the overall survival data. While we were unable
to evaluate or compare treatment-related side effects because of variation in data collection across the different
centers, we observed no significant difference in treatment completion rates between different radiotherapy or
chemo-radiotherapy regimens.
Our decision to include all eligible patients discussed atNeuro-OncologyMDTmeetings enabled us to document
that half of GBM patients aged 65 or over did not receive any chemotherapy or radiotherapy, and that a significant
proportion did not undergo neurosurgical intervention. While these figures appear high, most studies of elderly
GBM have excluded patients who have not undergone surgery or received active treatment, so very little data are
available for comparison. Our observation that median overall survival for patients receiving no treatment was only
2.5 months is in keeping with the outcome for elderly English patients reported by Brodbelt et al. [4] in 2015,
and provides some reassurance that these were appropriate management decisions. While it could be argued that
these patients might have experienced longer survival if they had been treated more actively, half of them had very
poor PS (ECOG PS ≥3) and over 60% were aged 75 and above. The favorable median survival of 11.5 months in
patients receiving chemo-radiation supports the patient selection philosophy of the centers who participated in the
study. Our findings indicate that survival data generated by clinical trials are not representative of the elderly GBM
population as a whole.
Conclusion
A large proportion of elderly GBM patients do not receive any oncological treatment. Hypofractionated chemo-
radiotherapy is being adopted as a treatment regimen in elderly patients with GBM in the UK. Our retrospective
study indicated that the patients receiving standard chemo-radiotherapy are at reduced risk of death compared with
patients receiving hypofractionated chemo-radiotherapy. While this result might reflect selection of patients with
better prognosis to be offered an extended treatment regimen, our analysis did not fully support this interpretation
and suggested that standard chemo-radiotherapy for GBM might improve outcomes for some patients. Robust
comparison of standard and hypofractionated regimens would require a randomized controlled trial.
Summary points
• Hypofractionated chemo-radiotherapy is being used in the UK as a treatment regimen in elderly patients with
glioblastoma (GBM).
• There was a trend for reduced risk of death for patients who received standard chemoradiation compared with
patients who received hypofractionated chemoradiation within the limitations of this retrospective study.
• A large proportion of elderly patients with GBM do not receive definitive treatment.
• Appropriate geriatric assessments are required to allow better assessment of elderly patients with GBM and
stratify treatment for these patients.
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